{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:21:41Z","timestamp":1792606901117,"version":"4.5.0"},"reference-count":301,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.thromres.2025.109504","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:29:12Z","timestamp":1760394552000},"page":"109504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The fibrinolytic system in disease: From molecular pathways to clinical outcomes"],"prefix":"10.1016","volume":"256","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9390-5645","authenticated-orcid":false,"given":"Mohamed Nazem","family":"Alibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled A.","family":"Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad S.","family":"Alshehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/019262339302100209","article-title":"An overview of hemostasis","volume":"21","author":"Boon","year":"1993","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/bja\/aei169","article-title":"Coagulopathy and blood component transfusion in trauma","volume":"95","author":"Spahn","year":"2005","journal-title":"Br. J. Anaesth."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0015","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1097\/00003246-199205000-00009","article-title":"Posttrauma coagulation and fibrinolysis","volume":"20","author":"Gando","year":"1992","journal-title":"Crit. Care Med."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/0192623310389474","article-title":"Continuing education course #2: current understanding of hemostasis","volume":"39","author":"Gale","year":"2011","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.thromres.2025.109504_bb0025","series-title":"StatPearls [Internet]","article-title":"Physiology, Hemostasis","author":"LaPelusa","year":"2023"},{"key":"10.1016\/j.thromres.2025.109504_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101157","article-title":"Contemporary tools for evaluation of hemostasis in neonates. Where are we and where are we headed?","volume":"64","author":"Sokou","year":"2024","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0035","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1152\/japplphysiol.00772.2016","article-title":"Vascular function and endothelin-1: tipping the balance between vasodilation and vasoconstriction","volume":"122","author":"Nishiyama","year":"1985","journal-title":"J. Appl. Physiol."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109504_bb0040","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.thromres.2007.03.011","article-title":"The role of von Willebrand factor in thrombus formation","volume":"120","author":"Ruggeri","year":"2007","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2025.109504_bb0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/UPO9781922064004.010","article-title":"Physiological haemostasis","author":"McRae","year":"2011","journal-title":"Mechanisms of Vascular"},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112772","article-title":"Platelets and their role in hemostasis and thrombosis-from physiology to pathophysiology and therapeutic implications","volume":"23","author":"Scridon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0055","doi-asserted-by":"crossref","first-page":"6320","DOI":"10.1038\/s41467-022-33796-7","article-title":"von Willebrand factor links primary hemostasis to innate immunity","volume":"13","author":"Drakeford","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.thromres.2025.109504_bb0060","series-title":"Modern Hematology: Biology and Clinical Management","first-page":"327","article-title":"Basic principles of hemostasis","author":"Hiller","year":"2007"},{"issue":"9","key":"10.1016\/j.thromres.2025.109504_bb0065","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/j.1538-7836.2010.03963.x","article-title":"Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis","volume":"8","author":"Mutch","year":"2010","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1084\/jem.187.3.329","article-title":"Adhesion of activated platelets to endothelial cells: evidence for a GPIIbIIIa-dependent bridging mechanism and novel roles for endothelial intercellular adhesion molecule 1 (ICAM-1), alphavbeta3 integrin, and GPIbalpha","volume":"187","author":"Bombeli","year":"1998","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0075","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4103\/0019-5049.144643","article-title":"Overview of the coagulation system","volume":"58","author":"Palta","year":"2014","journal-title":"Indian J. Anaesth."},{"key":"10.1016\/j.thromres.2025.109504_bb0080","article-title":"Physiology, Clotting Mechanism","author":"Garmo","year":"2023"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0085","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2025.109504_bb0090","first-page":"5262","article-title":"The role of fibrinolytic system in health and disease","volume":"23","author":"Kwaan","year":"2022","journal-title":"MDPI"},{"key":"10.1016\/j.thromres.2025.109504_bb0095","series-title":"Hematology E-Book: Basic Principles and Practice","author":"Hoffman","year":"2022"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109504_bb0100","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1538-7836.2007.02516.x","article-title":"Serpins in thrombosis, hemostasis and fibrinolysis","volume":"5","author":"Rau","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0105","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nm0796-725a","article-title":"Plasminogen and wound healing","volume":"2","author":"R\u00f8mer","year":"1996","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0110","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0002-9440(10)65060-2","article-title":"Disruption of the plasminogen gene in mice abolishes wound healing after myocardial infarction","volume":"156","author":"Creemers","year":"2000","journal-title":"Am. J. Pathol."},{"issue":"18","key":"10.1016\/j.thromres.2025.109504_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814179","article-title":"The fibrinolytic system and its measurement: history, current uses and future directions for diagnosis and treatment","volume":"24","author":"Hvas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb0120","first-page":"506","article-title":"Plasminogen levels in healthy volunteers-influence of age, sex, smoking and oral contraceptives","volume":"68","author":"Tait","year":"1992","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.celrep.2012.02.012","article-title":"The X-ray crystal structure of full-length human plasminogen","volume":"1","author":"Law","year":"2012","journal-title":"Cell Rep."},{"issue":"6425","key":"10.1016\/j.thromres.2025.109504_bb0130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0140-6736(46)91017-3","article-title":"Observations on fibrinolysis plasminogen, plasmin, and antiplasmin content of human blood","volume":"248","author":"Macfarlane","year":"1946","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000022461","article-title":"The haemostatic balance\u2013Astrup revisited","volume":"29","author":"Gaffney","year":"1999","journal-title":"Pathophysiol. Haemost. Thromb."},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb0140","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1182\/blood.2020008951","article-title":"Plasminogen: an enigmatic zymogen","volume":"137","author":"Keragala","year":"2021","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb0145","first-page":"1004","article-title":"Isolated familial plasminogen deficiency may not be a risk factor for thrombosis","volume":"76","author":"Tait","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0150","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00006982-200507000-00025","article-title":"Pharmacologic vitreolysis combining the two enzymes plasmin and hyaluronidase","volume":"25","author":"Gandorfer","year":"2005","journal-title":"Retina (Philadelphia, Pa.)"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0155","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","article-title":"Molecular mechanisms of fibrinolysis","volume":"129","author":"Cesarman-Maus","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2025.109504_bb0160","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0049-3848(01)00296-1","article-title":"Basic principles in thrombolysis: regulatory role of plasminogen","volume":"103","author":"Rijken","year":"2001","journal-title":"Thromb. Res."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb0165","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/jth.14157","article-title":"Regulation of plasminogen activation on cell surfaces and fibrin","volume":"16","author":"Urano","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0170","doi-asserted-by":"crossref","first-page":"982","DOI":"10.15252\/embr.201541681","article-title":"Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin","volume":"17","author":"De Lorenzi","year":"2016","journal-title":"EMBO Rep."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0175","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1432-1033.1978.tb12200.x","article-title":"On the kinetics of the reaction between human antiplasmin and plasmin","volume":"84","author":"Wiman","year":"1978","journal-title":"Eur. J. Biochem."},{"issue":"18","key":"10.1016\/j.thromres.2025.109504_bb0180","doi-asserted-by":"crossref","first-page":"9291","DOI":"10.1016\/S0021-9258(19)86843-6","article-title":"On the mechanism of the reaction between human alpha 2-antiplasmin and plasmin","volume":"254","author":"Wiman","year":"1979","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0185","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood.V51.4.563.563","article-title":"Fast-acting plasmin inhibitor in human plasma","volume":"51","author":"Collen","year":"1978","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0190","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2007-09-114215","article-title":"X-ray crystal structure of the fibrinolysis inhibitor \u03b12-antiplasmin","volume":"111","author":"Law","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0195","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0021-9258(19)75687-7","article-title":"Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin)","volume":"262","author":"Holmes","year":"1987","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0200","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1042\/bj2910623","article-title":"Different N-terminal forms of \u03b12-plasmin inhibitor in human plasma","volume":"291","author":"Bangert","year":"1993","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0049-3848(82)90029-9","article-title":"Synthesis of \u03b12-antiplasmin by rat liver cells","volume":"28","author":"H\u00f6gstorp","year":"1982","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0210","first-page":"372","article-title":"Synthesis and secretion of the fibrinolytic components, including \u03b12-antiplasmin, by a human hepatoma cell line","volume":"101","author":"Fair","year":"1983","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.thromres.2025.109504_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.608899","article-title":"Alpha2-antiplasmin: the devil you don\u2019t know in cerebrovascular and cardiovascular disease","volume":"7","author":"Singh","year":"2020","journal-title":"Frontiers in Cardiovascular Medicine"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1159\/000297966","article-title":"Novel hemostatic factor levels and risk of ischemic stroke: the atherosclerosis risk in communities (ARIC) study","volume":"29","author":"Suri","year":"2010","journal-title":"Cerebrovasc. Dis."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0225","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000171704.50395.ba","article-title":"Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA","volume":"65","author":"Marti-Fabregas","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.thromres.2025.109504_bb0230","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"191","article-title":"\u03b12-antiplasmin: new insights and opportunities for ischemic stroke","volume":"vol. 2017","author":"Reed","year":"2017"},{"key":"10.1016\/j.thromres.2025.109504_bb0235","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.expneurol.2014.02.009","article-title":"Reversing the deleterious effects of \u03b12-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke","volume":"255","author":"Houng","year":"2014","journal-title":"Exp. Neurol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0240","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jth.15647","article-title":"Alpha-2-macroglobulin in hemostasis and thrombosis: an underestimated old double-edged sword","volume":"20","author":"Lagrange","year":"2022","journal-title":"J. Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.thromres.2025.109504_bb0245","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1515\/hsz-2016-0329","article-title":"Structural and functional insight into pan-endopeptidase inhibition by \u03b12-macroglobulins","volume":"398","author":"Goulas","year":"2017","journal-title":"Biol. Chem."},{"issue":"07","key":"10.1016\/j.thromres.2025.109504_bb0250","first-page":"662","article-title":"Neutralization of human extrinsic (tissue-type) plasminogen activator in human plasma: no evidence for a specific inhibitor","volume":"46","author":"Korninger","year":"1981","journal-title":"Thromb. Haemost."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb0255","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3109\/00365518009095590","article-title":"Binding of urokinase to plasma proteinase inhibitors","volume":"40","author":"Holmberg","year":"1980","journal-title":"Scand. J. Clin. Lab. Invest."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0260","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1084\/jem.132.2.329","article-title":"Human plasma alpha 2-macroglobulin: an inhibitor of plasma kallikrein","volume":"132","author":"Harpel","year":"1970","journal-title":"J. Exp. Med."},{"issue":"6238","key":"10.1016\/j.thromres.2025.109504_bb0265","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/341162a0","article-title":"The LDL\u2013receptor\u2013related protein, LRP, is an apolipoprotein E-binding protein","volume":"341","author":"Beisiegel","year":"1989","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.thromres.2025.109504_bb0270","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1073\/pnas.89.16.7427","article-title":"Low density lipoprotein receptor-related protein\/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator","volume":"89","author":"Bu","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"15","key":"10.1016\/j.thromres.2025.109504_bb0275","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1016\/S0021-9258(17)33232-5","article-title":"Platelet alpha2-macroglobulin and alpha1-antitrypsin","volume":"251","author":"Nachman","year":"1976","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0280","article-title":"Assessment of a complete and classified platelet proteome from genome-wide transcripts of human platelets and megakaryocytes covering platelet functions","volume":"11","author":"Huang","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.thromres.2025.109504_bb0285","series-title":"Seminars in thrombosis and hemostasis","first-page":"216","article-title":"Protease nexins and cellular regulation","author":"Baker","year":"1986"},{"key":"10.1016\/j.thromres.2025.109504_bb0290","series-title":"Regulation of Fibrinolysis by Platelets","first-page":"417","author":"Mutch","year":"2019"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0295","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1242\/dev.119.4.1119","article-title":"Variable and multiple expression of protease Nexin-1 during mouse organogenesis and nervous system development","volume":"119","author":"Mansuy","year":"1993","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood-2009-04-217240","article-title":"Anticoagulant and antithrombotic properties of platelet protease nexin-1","volume":"115","author":"Boulaftali","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb0305","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1161\/CIRCULATIONAHA.110.000885","article-title":"Platelet protease nexin-1, a serpin that strongly influences fibrinolysis and thrombolysis","volume":"123","author":"Boulaftali","year":"2011","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0310","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1152\/nips.01369.2001","article-title":"Plasminogen activator inhibitor 1: physiological and pathophysiological roles","volume":"17","author":"Binder","year":"2002","journal-title":"Physiology"},{"key":"10.1016\/j.thromres.2025.109504_bb0315","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"356","article-title":"Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin","volume":"vol. 2013","author":"Declerck","year":"2013"},{"key":"10.1016\/j.thromres.2025.109504_bb0320","article-title":"WHO methods and data sources for life tables 1990-2016","author":"WHO, G","year":"2018","journal-title":"Global Health Estimates Technical Paper"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0325","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.3390\/ijms22052721","article-title":"A narrative review on plasminogen activator inhibitor-1 and its (patho) physiological role: to target or not to target?","volume":"22","author":"Sillen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.thromres.2025.109504_bb0330","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"395","article-title":"Forty years later and the role of plasminogen activator inhibitor type 2\/SERPINB2 is still an enigma","volume":"vol. 2011","author":"Lee","year":"2011"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0335","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1432-1033.1988.tb14162.x","article-title":"Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2","volume":"175","author":"Thorsen","year":"1988","journal-title":"Eur. J. Biochem."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb0340","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/j.1538-7836.2005.01420.x","article-title":"PAI-1 and atherothrombosis","volume":"3","author":"Vaughan","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0345","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/0006-291X(90)90909-7","article-title":"Plasminogen activator inhibitor 2 (PAI-2) is not inactivated by exposure to oxidants which can be released from activated neutrophils","volume":"166","author":"Baker","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb0350","doi-asserted-by":"crossref","first-page":"13852","DOI":"10.1016\/S0021-9258(18)92780-8","article-title":"The oxidative inactivation of plasminogen activator inhibitor type 1 results from a conformational change in the molecule and does not require the involvement of the P1\u2019methionine","volume":"266","author":"Strandberg","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.thromres.2025.109504_bb0355","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"431","article-title":"Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy","author":"\u00c5stedt","year":"1998"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0360","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevImmunol.v31.i1.20","article-title":"The role of SerpinB2 in immunity","volume":"31","author":"Schroder","year":"2011","journal-title":"Crit. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0365","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0130136","article-title":"SerpinB2 (PAI-2) modulates proteostasis via binding misfolded proteins and promotion of cytoprotective inclusion formation","volume":"10","author":"Lee","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.thromres.2025.109504_bb0370","series-title":"Fibrinolysis in Pregnancy: A study of Plasminogen Activator Inhibitors","author":"Kruithof","year":"1987"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0375","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1084\/jem.165.2.320","article-title":"Plasminogen activator-specific inhibitors produced by human monocytes\/macrophages","volume":"165","author":"Wohlwend","year":"1987","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.thromres.2025.109504_bb0380","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1111\/j.1742-4658.2005.04879.x","article-title":"The undecided serpin: the ins and outs of plasminogen activator inhibitor type 2","volume":"272","author":"Medcalf","year":"2005","journal-title":"FEBS J."},{"issue":"5\u20136","key":"10.1016\/j.thromres.2025.109504_bb0385","first-page":"310","article-title":"Concentration of C1 inhibitor in sera of healthy blood donors as studied by immunoenzymatic assay","volume":"8","author":"Gregorek","year":"1991","journal-title":"Complement Inflamm."},{"key":"10.1016\/j.thromres.2025.109504_bb0390","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"362","article-title":"C1-inhibitor: more than a serine protease inhibitor","author":"Zeerleder","year":"2011"},{"key":"10.1016\/j.thromres.2025.109504_bb0395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-800100-4.00002-7","article-title":"Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway","volume":"121","author":"Kaplan","year":"2014","journal-title":"Adv. Immunol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0400","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000486312","article-title":"Hereditary and acquired angioedema: heterogeneity of pathogenesis and clinical phenotypes","volume":"175","author":"Bova","year":"2018","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.thromres.2025.109504_bb0405","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s11739-010-0408-3","article-title":"Angioedema due to C1 inhibitor deficiency in 2010","volume":"5","author":"Cicardi","year":"2010","journal-title":"Intern. Emerg. Med."},{"key":"10.1016\/j.thromres.2025.109504_bb0410","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3389\/fimmu.2020.00794","article-title":"Patterns of C1-inhibitor\/plasma serine protease complexes in healthy humans and in hereditary angioedema patients","volume":"11","author":"Kajd\u00e1csi","year":"2020","journal-title":"Front. Immunol."},{"issue":"32","key":"10.1016\/j.thromres.2025.109504_bb0415","doi-asserted-by":"crossref","first-page":"21833","DOI":"10.1016\/S0021-9258(18)54713-X","article-title":"Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma","volume":"266","author":"Eaton","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0420","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.3390\/ijms22073670","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI): an updated narrative review","volume":"22","author":"Sillen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"03","key":"10.1016\/j.thromres.2025.109504_bb0425","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5482\/ha-1155","article-title":"Thrombin activatable fibrinolysis inhibitor","volume":"31","author":"Declerck","year":"2011","journal-title":"H\u00e4mostaseologie"},{"key":"10.1016\/j.thromres.2025.109504_bb0430","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"365","article-title":"Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis","volume":"vol. 2013","author":"Vercauteren","year":"2013"},{"key":"10.1016\/j.thromres.2025.109504_bb0435","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0006-2952(68)90307-9","article-title":"Role of blood coagulation in acute inflammation","volume":"17","author":"Barnhart","year":"1968","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.thromres.2025.109504_bb0440","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2119\/molmed.2010.00146","article-title":"Novel aspects of fibrin (ogen) fragments during inflammation","volume":"17","author":"Jennewein","year":"2011","journal-title":"Mol. Med."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0445","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/SHK.0b013e318264b95d","article-title":"The fibrinopeptide b\u03b215-42 reduces inflammation in mice subjected to polymicrobial sepsis","volume":"38","author":"Jennewein","year":"2012","journal-title":"Shock"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0450","first-page":"373","article-title":"The production of arthritis in rabbits by an immunological reaction to fibrin","volume":"43","author":"Dumonde","year":"1962","journal-title":"Br. J. Exp. Pathol."},{"key":"10.1016\/j.thromres.2025.109504_bb0455","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"143","article-title":"Plasmin: a modulator of immune function","volume":"vol. 2017","author":"Draxler","year":"2017"},{"key":"10.1016\/j.thromres.2025.109504_bb0460","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"135","article-title":"Plasmin (ogen) at the nexus of fibrinolysis, inflammation, and complement","volume":"vol. 2017","author":"Foley","year":"2017"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0465","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2014-01-549659","article-title":"Plasminogen promotes macrophage phagocytosis in mice","volume":"124","author":"Das","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0470","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0131216","article-title":"Dendritic cell-mediated phagocytosis but not immune activation is enhanced by plasmin","volume":"10","author":"Borg","year":"2015","journal-title":"PloS One"},{"issue":"05","key":"10.1016\/j.thromres.2025.109504_bb0475","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1160\/TH15-08-0653","article-title":"Plasminogen is a critical regulator of cutaneous wound healing","volume":"116","author":"Sulniute","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0480","doi-asserted-by":"crossref","first-page":"4303","DOI":"10.1016\/S0021-9258(18)89264-X","article-title":"Binding and activation of plasminogen on the platelet surface","volume":"260","author":"Miles","year":"1985","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0485","article-title":"So many plasminogen receptors: why?","volume":"2012","author":"Plow","year":"2012","journal-title":"Biomed. Res. Int."},{"issue":"24","key":"10.1016\/j.thromres.2025.109504_bb0490","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1182\/blood-2012-01-407825","article-title":"Plasminogen is a key proinflammatory regulator that accelerates the healing of acute and diabetic wounds","volume":"119","author":"Shen","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb0495","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2016-09-742825","article-title":"Plasmin and plasminogen induce macrophage reprogramming and regulate key steps of inflammation resolution via annexin A1","volume":"129","author":"Sugimoto","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109504_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109761","article-title":"The multifaceted role of plasminogen in inflammation","volume":"75","author":"Heissig","year":"2020","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0505","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180705","article-title":"Plasminogen-binding proteins as an evasion mechanism of the host\u2019s innate immunity in infectious diseases","volume":"38","author":"Ay\u00f3n-N\u00fa\u00f1ez","year":"2018","journal-title":"Biosci. Rep."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb0510","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/s41590-018-0232-x","article-title":"Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration","volume":"19","author":"Ryu","year":"2018","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0515","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuron.2019.01.014","article-title":"Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer\u2019s disease model","volume":"101","author":"Merlini","year":"2019","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0520","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.dld.2011.10.016","article-title":"Bleeding and thrombosis in cirrhotic patients: what really matters?","volume":"44","author":"Ferro","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.thromres.2025.109504_bb0525","first-page":"215","article-title":"Prevention and management of bleeding risk related to invasive procedures in cirrhosis, seminars in liver disease","volume":"2018","author":"Schepis","year":"2018","journal-title":"Thieme Medical Publishers"},{"issue":"285","key":"10.1016\/j.thromres.2025.109504_bb0530","first-page":"330","article-title":"Fibrinolysis in chronic hepatic insufficiency","volume":"25","author":"Goodpasture","year":"1914","journal-title":"Bull. Johns Hopkins Hosp."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0535","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109504_bb0540","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcrc.2017.07.053","article-title":"Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure","volume":"43","author":"Fisher","year":"2018","journal-title":"J. Crit. Care"},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0545","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1572-0241.2006.00588.x","article-title":"Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism","volume":"101","author":"Northup","year":"2006","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0550","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1055\/s-0038-1647518","article-title":"Uptake and degradation of tissue plasminogen activator in rat liver","volume":"59","author":"Einarsson","year":"1988","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0555","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/bj2380643","article-title":"Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats","volume":"238","author":"Rijken","year":"1986","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0560","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0268-9499(91)90053-7","article-title":"Tissue plasminogen activator and plasminogen activator inhibitor in patients with liver cirrhosis","volume":"5","author":"Lasierra","year":"1991","journal-title":"Fibrinolysis"},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0565","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1136\/jcp.37.7.772","article-title":"Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator","volume":"37","author":"Booth","year":"1984","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0570","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1182\/blood.V69.5.1315.1315","article-title":"The pathogenesis of accelerated fibrinolysis in liver cirrhosis: a critical role for tissue plasminogen activator inhibitor","volume":"69","author":"Hersch","year":"1987","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0575","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/hep.1840060115","article-title":"Hemostasis and fibrinolysis in severe liver failure and their relation to hemorrhage","volume":"6","author":"Boks","year":"1986","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0580","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.1840170115","article-title":"Hyperfibrinolysis resulting from clotting activation in patients with different degrees of cirrhosis. The CALC group. Coagulation abnormalities in liver cirrhosis","volume":"17","author":"Violi","year":"1993","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0585","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0049-3848(85)90164-1","article-title":"Plasma histidine-rich glycoprotein and plasminogen in patients with liver disease","volume":"39","author":"Gram","year":"1985","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0590","first-page":"493","article-title":"Histidine-rich glycoprotein is elevated in mild liver cirrhosis and decreased in moderate and severe liver cirrhosis","volume":"113","author":"Leebeek","year":"1989","journal-title":"J. Lab. Clin. Med."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0595","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1055\/s-0038-1646739","article-title":"Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen","volume":"39","author":"Biland","year":"1978","journal-title":"Thromb. Haemost."},{"issue":"1\u20132","key":"10.1016\/j.thromres.2025.109504_bb0600","first-page":"99","article-title":"The alpha2-plasmin inhibitor levels in liver diseases","volume":"84","author":"Aoki","year":"1978","journal-title":"Clin. Chim. Acta"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0605","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/hep.1840180611","article-title":"Activation of the fibrinolytic system in patients with fulminant liver failure","volume":"18","author":"Pernambuco","year":"1993","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0610","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0037-1615651","article-title":"Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease","volume":"85","author":"Van Thiel","year":"2001","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109504_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.608899","article-title":"Alpha2-antiplasmin: the devil you don\u2019t know in cerebrovascular and cardiovascular disease","volume":"7","author":"Singh","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"10.1016\/j.thromres.2025.109504_bb0620","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/j.1572-0241.1999.02801.x","article-title":"AICF and DIC in liver cirrhosis: expressions of a hypercoagulable state","volume":"94","author":"Joist","year":"1999","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.thromres.2025.109504_bb0625","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/hep.21303","article-title":"Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management","volume":"44","author":"Sh","year":"2006","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0630","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/hep.20569","article-title":"Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests","volume":"41","author":"Tripodi","year":"2005","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0635","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cld.2008.09.008","article-title":"Hyperfibrinolysis in liver disease","volume":"13","author":"Ferro","year":"2009","journal-title":"Clin. Liver Dis."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0640","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood.V68.1.275.275","article-title":"Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation","volume":"68","author":"Stricker","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109504_bb0645","series-title":"The Coagulopathy of Cirrhosis: Myth or Reality?","first-page":"434","volume":"Vol. 41","author":"Bosch","year":"2005"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0650","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/hep.1840150420","article-title":"Hyperfibrinolysis increases the risk of gastrointestinal hemorrhage in patients with advanced cirrhosis","volume":"15","author":"Violi","year":"1992","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.thromres.2025.109504_bb0655","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMra003007","article-title":"Gastroesophageal variceal hemorrhage","volume":"345","author":"Sharara","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0660","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bpg.2013.08.004","article-title":"Variceal and other portal hypertension related bleeding","volume":"27","author":"Turon","year":"2013","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb0665","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/lt.23668","article-title":"Intraoperative hypercoagulability during liver transplantation as demonstrated by thromboelastography","volume":"19","author":"Krzanicki","year":"2013","journal-title":"Liver Transpl."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0670","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41424-018-0002-y","article-title":"Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis","volume":"9","author":"Stine","year":"2018","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0675","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1055\/s-0038-1676954","article-title":"Haemostatic profiles are similar across all Aetiologies of cirrhosis","volume":"119","author":"Bos","year":"2019","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0680","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jhep.2016.06.001","article-title":"Preserved hemostatic status in patients with non-alcoholic fatty liver disease","volume":"65","author":"Potze","year":"2016","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0685","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1538-7836.2012.04770.x","article-title":"Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure","volume":"10","author":"Lisman","year":"2012","journal-title":"J. Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0690","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1002\/hep.31507","article-title":"VWF\/ADAMTS13 imbalance, but not global coagulation or fibrinolysis, is associated with outcome and bleeding in acute liver failure","volume":"73","author":"Driever","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0695","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.21779","article-title":"Role of the coagulation system in acetaminophen-induced hepatotoxicity in mice","volume":"46","author":"Ganey","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0700","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00007890-198906000-00012","article-title":"Systemic effects of tissue plasminogen activator-associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation","volume":"47","author":"Porte","year":"1989","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0705","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1182\/blood.V71.4.1090.1090","article-title":"Fibrinolysis during liver transplantation in humans: role of tissue-type plasminogen activator","volume":"71","author":"Dzik","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0710","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00007890-198906000-00012","article-title":"Systemic effects of tissue plasminogen activator\u2013associated fibrinolysis and its relation to thrombin generation in orthotopic liver transplantation","volume":"47","author":"Porte","year":"1989","journal-title":"Transplantation"},{"key":"10.1016\/j.thromres.2025.109504_bb0715","series-title":"Fibrinolysis during Liver Transplantation in Humans: Role of Tissue-Type Plasminogen Activator","author":"Dzik","year":"1988"},{"issue":"9212","key":"10.1016\/j.thromres.2025.109504_bb0720","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(00)02111-5","article-title":"Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study","volume":"355","author":"Porte","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0725","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1600-6143.2006.01591.x","article-title":"Efficacy and safety of antifibrinolytic drugs in liver transplantation: a systematic review and meta-analysis","volume":"7","author":"Molenaar","year":"2007","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.thromres.2025.109504_bb0730","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJMra003007","article-title":"Gastroesophageal variceal hemorrhage","volume":"345","author":"Sharara","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0735","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bpg.2013.08.004","article-title":"Variceal and other portal hypertension related bleeding","volume":"27","author":"Turon","year":"2013","journal-title":"Best Pract. Res. Clin. Gastroenterol."},{"issue":"10241","key":"10.1016\/j.thromres.2025.109504_bb0740","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)30848-5","article-title":"Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial","volume":"395","author":"Roberts","year":"2020","journal-title":"The Lancet"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0745","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/hep.30915","article-title":"Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival","volume":"71","author":"Blasi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.thromres.2025.109504_bb0750","series-title":"Pathophysiology and Management of Hemostatic Alterations in Cirrhosis and Liver Transplantation","author":"Arshad","year":"2016"},{"key":"10.1016\/j.thromres.2025.109504_bb0755","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"601","article-title":"Fibrinolysis in patients with liver disease","volume":"vol. 2021","author":"von Meijenfeldt","year":"2021"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0760","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1182\/blood-2010-02-261891","article-title":"Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences","volume":"116","author":"Lisman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2025.109504_bb0765","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcrc.2017.07.053","article-title":"Balanced haemostasis with both hypo-and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure","volume":"43","author":"Fisher","year":"2018","journal-title":"J. Crit. Care"},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0770","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1111\/jth.15364","article-title":"Treatment of bleeding in patients with liver disease","volume":"19","author":"Northup","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0775","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1211801","article-title":"Transfusion strategies for acute upper gastrointestinal bleeding","volume":"368","author":"Villanueva","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0780","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/gut.15.2.99","article-title":"The portal pressure-blood volume relationship in cirrhosis","volume":"15","author":"Zimmon","year":"1974","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0785","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/MCG.0000000000001214","article-title":"Thromboelastography-guided blood product transfusion in cirrhosis patients with variceal bleeding: a randomized controlled trial","volume":"54","author":"Rout","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0790","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","article-title":"Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia","volume":"155","author":"Terrault","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0795","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/hep.30561","article-title":"Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2)","volume":"70","author":"Peck-Radosavljevic","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0800","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1080\/09537104.2020.1859102","article-title":"The efficacy and safety of thrombopoietin receptor agonists in patients with chronic liver disease undergoing elective procedures: a systematic review and meta-analysis","volume":"33","author":"Lindquist","year":"2022","journal-title":"Platelets"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2017.04.052","article-title":"Global, regional, and National Burden of cardiovascular diseases for 10 causes, 1990 to 2015","volume":"70","author":"Roth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb0810","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.jacc.2009.11.051","article-title":"A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques","volume":"55","author":"Reininger","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0815","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00016.2011","article-title":"New fundamentals in hemostasis","volume":"93","author":"Versteeg","year":"2013","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.thromres.2025.109504_bb0820","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"490","article-title":"Fibrinolysis in acute and chronic cardiovascular disease","volume":"vol. 2021","author":"Kietsiriroje","year":"2021"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0825","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1055\/s-0037-1613368","article-title":"Molecular mechanisms of initiation of fibrinolysis by fibrin","volume":"89","author":"Medved","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109504_bb0830","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1111\/jth.12935","article-title":"Basic mechanisms and regulation of fibrinolysis","volume":"13","author":"Longstaff","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb0835","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/00001721-199509000-00011","article-title":"Effect of fibrin structure on plasmin-mediated dissolution of plasma clots","volume":"6","author":"Carr","year":"1995","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0840","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1161\/01.ATV.20.5.1354","article-title":"Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy","volume":"20","author":"Collet","year":"2000","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"34","key":"10.1016\/j.thromres.2025.109504_bb0845","doi-asserted-by":"crossref","first-page":"24259","DOI":"10.1016\/S0021-9258(18)35759-4","article-title":"The effect of fibrin structure on fibrinolysis","volume":"267","author":"Gabriel","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0850","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1161\/ATVBAHA.119.313626","article-title":"Effects of post-translational modifications of fibrinogen on clot formation, clot structure, and fibrinolysis: a systematic review","volume":"40","author":"de Vries","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb0855","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2002-08-2527","article-title":"Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk","volume":"101","author":"Wolberg","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0860","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1160\/TH09-05-0306","article-title":"The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis","volume":"103","author":"He","year":"2010","journal-title":"Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109504_bb0865","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/jth.12229","article-title":"Fibrin(ogen) and thrombotic disease","volume":"11","author":"Ariens","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0870","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1538-7836.2004.01055.x","article-title":"Discovery of alpha2-plasmin inhibitor and its congenital deficiency","volume":"3","author":"Aoki","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2025.109504_bb0875","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jth.12216","article-title":"Insights into thrombin activatable fibrinolysis inhibitor function and regulation","volume":"11","author":"Foley","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0880","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0038-1650232","article-title":"Proteins of the fibrinolytic system in human thrombi","volume":"75","author":"Robbie","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.thromres.2025.109504_bb0885","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJM200006153422406","article-title":"Plasminogen-activator inhibitor type 1 and coronary artery disease","volume":"342","author":"Kohler","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109504_bb0890","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.02.135","article-title":"Role of plasminogen activator inhibitor-1 in coronary pathophysiology","volume":"164","author":"Jung","year":"2018","journal-title":"Thromb. Res."},{"issue":"22","key":"10.1016\/j.thromres.2025.109504_bb0895","doi-asserted-by":"crossref","first-page":"18831","DOI":"10.1074\/jbc.M111.323287","article-title":"Plasminogen is a complement inhibitor","volume":"287","author":"Barthel","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0900","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0905","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"Undas","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0910","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0915","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1160\/TH16-09-0712","article-title":"Impaired thrombolytic status predicts adverse cardiac events in patients undergoing primary percutaneous coronary intervention","volume":"117","author":"Christopoulos","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.thromres.2025.109504_bb0920","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"13","key":"10.1016\/j.thromres.2025.109504_bb0925","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb0930","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1160\/TH16-12-0954","article-title":"Fibrin clot characteristics in acute ischaemic stroke patients treated with thrombolysis: the impact on clinical outcome","volume":"117","author":"Bembenek","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb0935","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1365-2141.2011.08935.x","article-title":"Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study","volume":"156","author":"Siegerink","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0940","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.thromres.2006.08.005","article-title":"Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia","volume":"120","author":"Anzej","year":"2007","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb0945","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s11239-019-01826-9","article-title":"Restenosis is associated with prothrombotic plasma fibrin clot characteristics in endovascularly treated patients with critical limb ischemia","volume":"47","author":"Nowakowski","year":"2019","journal-title":"J. Thromb. Thrombolysis"},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb0950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0027852","article-title":"Anticoagulants and the propagation phase of thrombin generation","volume":"6","author":"Orfeo","year":"2011","journal-title":"PloS One"},{"issue":"14","key":"10.1016\/j.thromres.2025.109504_bb0955","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0960","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109504_bb0965","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"589","article-title":"Fibrinolytic alterations in sepsis: biomarkers and future treatment targets","volume":"2021","author":"Larsen","year":"2021"},{"key":"10.1016\/j.thromres.2025.109504_bb0970","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"392","article-title":"Role of fibrinolysis in sepsis","volume":"vol. 2013","author":"Gando","year":"2013"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb0975","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1182\/blood.V76.12.2520.2520","article-title":"Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways","volume":"76","author":"van Deventer","year":"1990","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.thromres.2025.109504_bb0980","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1056\/NEJM198905043201802","article-title":"Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects","volume":"320","author":"Suffredini","year":"1989","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb0985","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1182\/blood.V86.3.1027.1027","volume":"86","author":"Jansen","year":"1995","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb0990","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1055\/s-0038-1650653","article-title":"Interleukin-6 stimulates coagulation, not fibrinolysis, in humans","volume":"76","author":"Stouthard","year":"1996","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb0995","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0038-1657303","article-title":"Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis","volume":"49","author":"Osterud","year":"1983","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1000","first-page":"56","article-title":"Plasminogen activator inhibitor 1: physiological and pathophysiological roles","volume":"17","author":"Binder","year":"2002","journal-title":"News Physiol. Sci."},{"issue":"28","key":"10.1016\/j.thromres.2025.109504_bb1005","doi-asserted-by":"crossref","first-page":"16603","DOI":"10.1074\/jbc.271.28.16603","article-title":"TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex","volume":"271","author":"Bajzar","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/07853890600852898","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI)\u2014how does thrombin regulate fibrinolysis?","volume":"38","author":"Bouma","year":"2006","journal-title":"Ann. Med."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00001721-200106000-00008","article-title":"Depressed plasma activity of plasminogen or alpha2 plasmin inhibitor is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation","volume":"12","author":"Asakura","year":"2001","journal-title":"Blood Coagul. Fibrinolysis"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb1020","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00134-001-1139-8","article-title":"Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock","volume":"27","author":"Mavrommatis","year":"2001","journal-title":"Intensive Care Med."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1025","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jth.15112","article-title":"Global hemostatic status in patients with acute-on-chronic liver failure and septics without underlying liver disease","volume":"19","author":"Lisman","year":"2021","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1030","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1538-7836.2005.01697.x","article-title":"Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation","volume":"4","author":"Kienast","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb1035","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/j.1538-7836.2004.00955.x","article-title":"Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation 1","volume":"2","author":"Dhainaut","year":"2004","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1040","doi-asserted-by":"crossref","DOI":"10.1186\/cc12783","article-title":"A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis","volume":"17","author":"Gando","year":"2013","journal-title":"Crit. Care"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb1045","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1161\/ATVBAHA.115.306035","article-title":"Cell-free DNA modulates clot structure and impairs fibrinolysis in Sepsis","volume":"35","author":"Gould","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1050","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/1479164111432788","article-title":"Complement C3 is a novel plasma clot component with anti-fibrinolytic properties","volume":"9","author":"Howes","year":"2012","journal-title":"Diab. Vasc. Dis. Res."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1055","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3904\/kjim.1999.14.2.72","article-title":"The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis","volume":"14","author":"Park","year":"1999","journal-title":"Korean J. Intern. Med."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1060","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.thromres.2012.01.015","article-title":"A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis","volume":"130","author":"Hayakawa","year":"2012","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.CCM.0000153520.31562.48","article-title":"Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure","volume":"33","author":"Dhainaut","year":"2005","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1070","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MCG.0000000000001327","article-title":"Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis","volume":"54","author":"Lisman","year":"2020","journal-title":"J. Clin. Gastroenterol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1075","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.CIR.91.4.1175","article-title":"Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody","volume":"91","author":"Biemond","year":"1995","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1080","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1055\/s-0038-1656086","article-title":"The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis","volume":"77","author":"van Giezen","year":"1997","journal-title":"Thromb. Haemost."},{"issue":"14","key":"10.1016\/j.thromres.2025.109504_bb1085","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1021\/jm049766q","article-title":"Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization","volume":"47","author":"Elokdah","year":"2004","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.thromres.2025.109504_bb1090","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2008.03063.x","article-title":"Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis","volume":"6","author":"Hennan","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109504_bb1095","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110528","article-title":"Embelin ameliorated sepsis-induced disseminated intravascular coagulation intensities by simultaneously suppressing inflammation and thrombosis","volume":"130","author":"Wang","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb1100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136463","article-title":"Assessment of fibrinolysis in sepsis patients with urokinase modified thromboelastography","volume":"10","author":"Panigada","year":"2015","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1105","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00134-016-4221-y","article-title":"Impaired dynamics of clot formation and hypofibrinolysis in severe sepsis are coexisting and strictly related","volume":"42","author":"Panigada","year":"2016","journal-title":"Intensive Care Med."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1110","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcrc.2014.04.019","article-title":"Association between early glycemic control and improvements in markers of coagulation and fibrinolysis in patients with septic shock\u2013induced stress hyperglycemia","volume":"29","author":"Sanches","year":"2014","journal-title":"J. Crit. Care"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1115","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCM.0b013e31819542da","article-title":"Tight glycemic control may favor fibrinolysis in patients with sepsis","volume":"37","author":"Savioli","year":"2009","journal-title":"Crit. Care Med."},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb1120","doi-asserted-by":"crossref","first-page":"14270","DOI":"10.1096\/fj.201901363RRR","article-title":"DNA-bound elastase of neutrophil extracellular traps degrades plasminogen, reduces plasmin formation, and decreases fibrinolysis: proof of concept in septic shock plasma","volume":"33","author":"Cruz","year":"2019","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-016-0076-2","article-title":"Validation of a modified thromboelastometry approach to detect changes in fibrinolytic activity","volume":"14","author":"Kuiper","year":"2016","journal-title":"Thromb. J."},{"issue":"17","key":"10.1016\/j.thromres.2025.109504_bb1130","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.3390\/jcm14176055","article-title":"The fibrinolytic system in bacterial sepsis: a comprehensive review of current assessment methods","volume":"14","author":"Scarlatescu","year":"2025","journal-title":"Journal of Clinical Medicine"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2016.01.006","article-title":"Acute fibrinolysis shutdown after injury occurs frequently and increases mortality: a multicenter evaluation of 2,540 severely injured patients","volume":"222","author":"Moore","year":"2016","journal-title":"J. Am. Coll. Surg."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/TA.0000000000001308","article-title":"Abnormalities in fibrinolysis at the time of admission are associated with deep vein thrombosis, mortality, and disability in a pediatric trauma population","volume":"82","author":"Leeper","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00068-017-0833-3","article-title":"Fibrinolysis in trauma: a review","volume":"44","author":"Madurska","year":"2018","journal-title":"Eur. J. Trauma Emerg. Surg."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1150","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/TA.0000000000000341","article-title":"Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: the spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy","volume":"77","author":"Moore","year":"2014","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.thromres.2025.109504_bb1155","series-title":"Trauma induced coagulopathy","first-page":"135","article-title":"Fibrinolysis","author":"Moore","year":"2016"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1160","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/01.sla.0000256862.79374.31","article-title":"Acute traumatic coagulopathy: initiated by hypoperfusion: modulated through the protein C pathway?","volume":"245","author":"Brohi","year":"2007","journal-title":"Ann. Surg."},{"issue":"50","key":"10.1016\/j.thromres.2025.109504_bb1165","doi-asserted-by":"crossref","first-page":"36040","DOI":"10.1074\/jbc.M113.491324","article-title":"NAT8L (N-acetyltransferase 8-like) accelerates lipid turnover and increases energy expenditure in brown adipocytes","volume":"288","author":"Pessentheiner","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/ALN.0000000000001428","article-title":"Activated protein C drives the Hyperfibrinolysis of acute traumatic coagulopathy","volume":"126","author":"Davenport","year":"2017","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hoc.2006.11.004","article-title":"Coagulation 2006: a modern view of hemostasis","volume":"21","author":"Hoffman","year":"2007","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1180","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jamcollsurg.2012.06.005","article-title":"Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma","volume":"215","author":"Ives","year":"2012","journal-title":"J. Am. Coll. Surg."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1185","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/TA.0000000000001304","article-title":"Sympathoadrenal activation and endotheliopathy are drivers of hypocoagulability and hyperfibrinolysis in trauma: a prospective observational study of 404 severely injured patients","volume":"82","author":"Ostrowski","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1190","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jcp.22.6.659","article-title":"Reaction pattern to three stresses--electroplexy, surgery, and myocardial infarction--of fibrinolysis and plasma fibrinogen","volume":"22","author":"Chakrabarti","year":"1969","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1195","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/TA.0000000000001379","article-title":"Tissue injury suppresses fibrinolysis after hemorrhagic shock in nonhuman primates (rhesus macaque)","volume":"82","author":"Macko","year":"2017","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.thromres.2025.109504_bb1200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1757-7241-17-45","article-title":"Thrombelastography and tromboelastometry in assessing coagulopathy in trauma","volume":"17","author":"Johansson","year":"2009","journal-title":"Scand. J. Trauma Resusc. Emerg. Med."},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb1205","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1590\/S0100-879X2009001200015","article-title":"Normal range values for thromboelastography in healthy adult volunteers","volume":"42","author":"Scarpelini","year":"2009","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1210","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1097\/TA.0b013e318292cc54","article-title":"Tranexamic acid in trauma: how should we use it?","volume":"74","author":"Napolitano","year":"2013","journal-title":"J. Trauma Acute Care Surg."},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1215","first-page":"612","article-title":"Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2) a randomised, placebo-controlled trial","volume":"59","author":"Williams-Johnson","year":"2010","journal-title":"West Indian Med. J."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1220","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pestbp.2011.02.012","article-title":"Investigations of the constitutive overexpression of CYP6D1 in the permethrin resistant LPR strain of house fly (Musca domestica)","volume":"100","author":"Lin","year":"2011","journal-title":"Pestic. Biochem. Physiol."},{"key":"10.1016\/j.thromres.2025.109504_bb1225","series-title":"Seminars in Thrombosis and Hemostasis","first-page":"200","article-title":"Fibrinolysis in trauma:\u201cmyth,\u201d\u201creality,\u201d or \u201csomething in between\u201d","volume":"vol. 2017","author":"Walsh","year":"2017"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1592\/phco.27.6.860","article-title":"Emerging role of anticoagulants and fibrinolytics in the treatment of acute respiratory distress syndrome","volume":"27","author":"MacLaren","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1235","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/000313480106700417","article-title":"Treatment of severe acute respiratory distress syndrome: a final report on a phase I study","volume":"67","author":"Hardaway","year":"2001","journal-title":"Am. Surg."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1240","doi-asserted-by":"crossref","first-page":"5112","DOI":"10.1038\/s41598-020-59526-x","article-title":"The distinctive structure and composition of arterial and venous thrombi and pulmonary emboli","volume":"10","author":"Chernysh","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1245","article-title":"Pulmonary embolism and deep vein thrombosis\u2014comorbidities and temporary provoking factors in a register-based study of 1.48 million people","volume":"6","author":"Sandblad","year":"2022","journal-title":"Research and Practice in Thrombosis and Haemostasis"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1250","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.10.014","article-title":"Lifetime risk of venous thromboembolism in two cohort studies","volume":"129","author":"Bell","year":"2016","journal-title":"Am. J. Med."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb1255","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.3390\/medicina58081078","article-title":"Pathophysiological aspects of aging in venous thromboembolism: an update","volume":"58","author":"Akrivou","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.thromres.2025.109504_bb1260","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01348","article-title":"Fibrinolysis and inflammation in venous thrombus resolution","volume":"10","author":"Mukhopadhyay","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.thromres.2025.109504_bb1265","first-page":"819","article-title":"Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo","volume":"209","author":"von Bruhl","year":"2012"},{"key":"10.1016\/j.thromres.2025.109504_bb1270","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1016\/S0049-3848(09)70148-3","article-title":"Thrombus resolution and vein wall injury: dependence on chemokines and leukocytes","volume":"123","author":"Henke","year":"2009","journal-title":"Thromb. Res."},{"issue":"1\u20133","key":"10.1016\/j.thromres.2025.109504_bb1275","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.forsciint.2009.12.008","article-title":"Time-dependent organic changes of intravenous thrombi in stasis-induced deep vein thrombosis model and its application to thrombus age determination","volume":"195","author":"Nosaka","year":"2010","journal-title":"Forensic Sci. Int."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1280","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapin","year":"2015","journal-title":"Blood Rev."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1285","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jvs.2012.02.054","article-title":"The role of urokinase plasminogen activator and plasmin activator inhibitor-1 on vein wall remodeling in experimental deep vein thrombosis","volume":"56","author":"Baldwin","year":"2012","journal-title":"J. Vasc. Surg."},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017229","article-title":"Plasmin inhibitors prevent leukocyte accumulation and remodeling events in the postischemic microvasculature","volume":"6","author":"Reichel","year":"2011","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1295","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/jcp.10126","article-title":"Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism","volume":"192","author":"Monea","year":"2002","journal-title":"J. Cell. Physiol."},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1300","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1242\/jcs.114.5.917","article-title":"Matrix metalloproteinase-1 and-9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices","volume":"114","author":"Davis","year":"2001","journal-title":"J. Cell Sci."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1305","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1365-2141.2009.07601.x","article-title":"Post-thrombotic syndrome: prevalence, prognostication and need for progress","volume":"145","author":"Prandoni","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1310","first-page":"216","article-title":"The","volume":"2010","author":"Kahn","year":"2010","journal-title":"American Society of Hematology Education Program Book 2010"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1315","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/jth.12180","article-title":"Post-thrombotic syndrome: a clinical review","volume":"11","author":"Baldwin","year":"2013","journal-title":"J. Thromb. Haemost."},{"issue":"03","key":"10.1016\/j.thromres.2025.109504_bb1320","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1160\/TH08-08-0511","article-title":"Levels of inflammatory markers and the development of the post-thrombotic syndrome","volume":"101","author":"Shbaklo","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2025.109504_bb1325","series-title":"Seminars in Interventional Radiology","first-page":"016","article-title":"Multifaceted management of the postthrombotic syndrome","volume":"vol 2012","author":"Nayak","year":"2012"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1330","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1067\/mva.2002.121066","article-title":"Coagulation, fibrinolysis, and recanalization after acute deep venous thrombosis","volume":"35","author":"Meissner","year":"2002","journal-title":"J. Vasc. Surg."},{"issue":"10264","key":"10.1016\/j.thromres.2025.109504_bb1335","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(20)32439-9","article-title":"Direct oral anticoagulants: evidence and unresolved issues","volume":"396","author":"Chan","year":"2020","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.thromres.2025.109504_bb1340","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s10753-023-01848-9","article-title":"Protective role of endothelial SIRT1 in deep vein thrombosis and hypoxia-induced endothelial dysfunction mediated by NF-\u03baB deacetylation","volume":"46","author":"Tang","year":"2023","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1345","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.028056","article-title":"Chymase inhibition resolves and prevents deep vein thrombosis without increasing bleeding time in the mouse model","volume":"12","author":"Lapointe","year":"2023","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.thromres.2025.109504_bb1350","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/CIRCRESAHA.117.311185","article-title":"Mast cells granular contents are crucial for deep vein thrombosis in mice","volume":"121","author":"Ponomaryov","year":"2017","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1355","doi-asserted-by":"crossref","first-page":"195","DOI":"10.14797\/mdcj-12-4-195","article-title":"Epidemiology and pathophysiology of chronic thromboembolic pulmonary hypertension: risk factors and mechanisms","volume":"12","author":"Medrek","year":"2016","journal-title":"Methodist Debakey Cardiovasc. J."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.14797\/mdcj-14-3-219","article-title":"Pharmacologic and pharmacomechanical thrombolysis for acute deep vein thrombosis: focus on ATTRACT CME","volume":"14","author":"Comerota","year":"2018","journal-title":"Methodist Debakey Cardiovasc. J."},{"issue":"23","key":"10.1016\/j.thromres.2025.109504_bb1365","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa1615066","article-title":"Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis","volume":"377","author":"Vedantham","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.thromres.2025.109504_bb1370","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1161\/ATVBAHA.123.318781","article-title":"New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors","volume":"43","author":"Chan","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1375","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb1380","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.LBA-1.LBA-1","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"124","author":"Buller","year":"2014","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.thromres.2025.109504_bb1385","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.thromres.2025.109504_bb1390","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1395","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/j.1365-2516.2008.01831.x","article-title":"Rare inherited disorders of fibrinogen","volume":"14","author":"Acharya","year":"2008","journal-title":"Haemophilia"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1400","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2516.2008.01825.x","article-title":"Plasminogen deficiency","volume":"14","author":"Mehta","year":"2008","journal-title":"Haemophilia"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1405","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/hae.70019","article-title":"Safety and efficacy of long-term treatment of type 1 plasminogen deficient patients with intravenous plasminogen replacement therapy","volume":"31","author":"Shapiro","year":"2025","journal-title":"Haemophilia"},{"issue":"12","key":"10.1016\/j.thromres.2025.109504_bb1410","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1182\/blood-2017-09-806729","article-title":"Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency","volume":"131","author":"Shapiro","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.thromres.2025.109504_bb1415","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/hae.14849","article-title":"Plasminogen, human-tvmh for the treatment of children and adults with plasminogen deficiency type 1","volume":"29","author":"Shapiro","year":"2023","journal-title":"Haemophilia"},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1420","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41598-023-50445-1","article-title":"A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19","volume":"14","author":"Hirai","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1425","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12959-021-00303-9","article-title":"Tranexamic acid for the prevention and treatment of bleeding in surgery, trauma and bleeding disorders: a narrative review","volume":"19","author":"Ockerman","year":"2021","journal-title":"Thromb. J."},{"issue":"1","key":"10.1016\/j.thromres.2025.109504_bb1430","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s12884-022-04530-4","article-title":"Safety and efficacy of preoperative tranexamic acid in reducing intraoperative and postoperative blood loss in high-risk women undergoing cesarean delivery: a randomized controlled trial","volume":"22","author":"Shalaby","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"issue":"2","key":"10.1016\/j.thromres.2025.109504_bb1435","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jama.2019.20687","article-title":"Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial","volume":"323","author":"Weitz","year":"2020","journal-title":"Jama"},{"issue":"05","key":"10.1016\/j.thromres.2025.109504_bb1440","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1055\/a-1653-4699","article-title":"Reduced-dose intravenous thrombolysis for acute intermediate\u2013high-risk pulmonary embolism: rationale and design of the pulmonary embolism international THrOmbolysis (PEITHO)-3 trial","volume":"122","author":"Sanchez","year":"2022","journal-title":"Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.thromres.2025.109504_bb1445","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1016\/j.jtha.2023.04.037","article-title":"Inhibition of thrombin-activatable fibrinolysis inhibitor via DS-1040 to accelerate clot lysis in patients with acute pulmonary embolism: a randomized phase 1b study","volume":"21","author":"Vanassche","year":"2023","journal-title":"J. Thromb. Haemost."},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb1450","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb1455","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb1460","doi-asserted-by":"crossref","first-page":"800","DOI":"10.7326\/0003-4819-158-11-201306040-00004","article-title":"Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial","volume":"158","author":"Anderson","year":"2013","journal-title":"Ann. Intern. Med."},{"issue":"13","key":"10.1016\/j.thromres.2025.109504_bb1465","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.thromres.2025.109504_bb1470","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-031657","article-title":"CRISTAL: protocol for a cluster randomised, crossover, non-inferiority trial of aspirin compared to low molecular weight heparin for venous thromboembolism prophylaxis in hip or knee arthroplasty, a registry nested study","volume":"9","author":"Sidhu","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1475","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060000","article-title":"Randomised comparative effectiveness trial of pulmonary embolism prevention after hiP and kneE replacement (PEPPER): the PEPPER trial protocol","volume":"12","author":"Pellegrini","year":"2022","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1480","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/cvr\/cvab078","article-title":"Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials","volume":"118","author":"Joseph","year":"2022","journal-title":"Cardiovasc. Res."},{"issue":"21","key":"10.1016\/j.thromres.2025.109504_bb1485","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Yusuf","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2025.109504_bb1490","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.thromres.2022.03.014","article-title":"Prevention of post-thrombotic syndrome with rosuvastatin: a multicenter randomized controlled pilot trial (SAVER)","volume":"213","author":"Delluc","year":"2022","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.thromres.2025.109504_bb1495","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.thromres.2025.109504_bb1500","first-page":"785","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet","volume":"5","author":"Ghofrani","year":"2017","journal-title":"Respir. Med."},{"issue":"3","key":"10.1016\/j.thromres.2025.109504_bb1505","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S2213-2600(18)30367-9","article-title":"Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial","volume":"7","author":"Sadushi-Kolici","year":"2019","journal-title":"Lancet Respir. Med."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384825002543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:40:55Z","timestamp":1781019655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384825002543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":301,"alternative-id":["S0049384825002543"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109504","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The fibrinolytic system in disease: From molecular pathways to clinical outcomes","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2025.109504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109504"}}